Registered number: 11852368

ALPHA MD LTD

UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 MARCH 2023

THURSDAY



A16

14/12/2023 COMPANIES HOUSE

#91

ALPHA MD LTD REGISTERED NUMBER: 11852368

BALANCE SHEET AS AT 31 MARCH 2023

AS AT 31 WARCH 2023							
	Note		2023 £		2022 £		
Fixed assets							
Intangible fixed assets	4		106,019		-		
Investments	5		8		8		
		•	106,027	•	8		
Current assets							
Debtors: amounts falling due within one year	6	223,566		195,038			
Cash at bank and in hand		7,758		6,451			
	•	231,324		201,489			
Creditors: amounts falling due within one year	7	(710,212)		(458,748)			
Net current liabilities	•		(478,888)		(257,259)		
Net liabilities		·	(372,861)	-	(257,251)		
Capital and reserves		-		-			
Called up share capital			501		501		
Profit and loss account			(373,362)		(257,752)		
		-	(372,861)	•	(257,251)		

ALPHA MD LTD REGISTERED NUMBER: 11852368

BALANCE SHEET (CONTINUED) AS AT 31 MARCH 2023

The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 8 December 2023

D Barasara

Director

The notes on pages 3 to 7 form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

1. General information

Alpha MD Limited is a private limited company incorporated in England and Wales within the United Kingdom. The address of the registered office is given in the company's information page of these financial statements.

The company's functional and presentational currency is GBP and the financial statements are rounded to the nearest £.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

2.2 Exemption from preparing consolidated financial statements

The Company, and the Group headed by it, qualify as small as set out in section 383 of the Companies Act 2006 and the parent and Group are considered eligible for the exemption to prepare consolidated accounts.

2.3 Going concern

These financial statements have been prepared on the going concern basis. The company made a loss of £115,610 (2022: £95,929) in the year and had net liabilities of £372,861 (2022: £257,251). The company's shareholder has indicated that he will provide financial support to ensure the company can continue to trade for the foreseeable future and that he has the means to do so. On this basis, the director considers it appropriate to continue to prepare the financial statements on the going concern basis.

2.4 Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:

- the amount of revenue can be measured reliably;
- it is probable that the Company will receive the consideration due under the contract;
- the stage of completion of the contract at the end of the reporting period can be measured reliably; and
- the costs incurred and the costs to complete the contract can be measured reliably.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

2. Accounting policies (continued)

2.5 Research and development

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which range from 3 to 6 years.

If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

2.6 Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

2.7 Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life should not exceed 10 years.

The estimated useful life of the software development is 5 years.

2.8 Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

2.9 Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

2.10 Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

2.11 Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

2. Accounting policies (continued)

2.12 Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.

Development

3. Employees

The average monthly number of employees, including directors, during the year was 1 (2022 - 1).

4. Intangible assets

,	expenditure £
Cost	
Additions	132,524
At 31 March 2023	132,524
Amortisation	
Charge for the year	26,505
At 31 March 2023	26,505
Net book value	
At 31 March 2023	106,019
At 31 March 2022	<u>-</u>

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

5.	Fixed asset investments			•
				Investments in subsidiary company
				£
	Cost At 1 April 2022			. 8
**	At 31 March 2023		-	8
	Subsidiary undertaking	and the confidence of the con- grade to with a light of the		
	The following was a subsidiary undertaking of the	Company:		
	Name	Registered office	Class of shares	Holding
	Liberate Pro Healthcare Ltd	2 London Wall Place, London, UK	Ordinary shares	80%
6.	Debtors			
		٠	2023 £	2022 £
	Amounts owed by group undertakings		222,770	190,870
	Other debtors		373	3,770
	Prepayments and accrued income		423	398
		=	223,566	195,038
7.	Creditors: Amounts falling due within one yea	ar		
			2023	2022
			£	£
	Amounts owed to group undertakings		702,011	455, 133
	Other taxation and social security		952	_
	Other creditors		4,649	1,115
	Accruals and deferred income		2,600	2,500
			710,212	458,748

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

8. Related party transactions

As at year end, £702,011 (2022: £455,133) was owed to Alpha MD Pvt Ltd, the parent undertaking of the company and £222,770 (2022: £190,870) was due from Liberate Pro Healthcare Ltd, a subisidary of the company.

These amounts are repayable on demand and interests free.

During the year, Apha MD Pvt Ltd charged management charges of £69,380 (2022: £33,600).

9. Controlling party

The immediate and ultimate parent undertaking is Alpha MD Pvt Ltd, a company registered in India. The ultimate controlling party is J D Barasara.